Tesamorelin · research summary

Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.

Cureus · 2025. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Retrospective pharmacovigilance analysis using the FAERS database
“A retrospective pharmacovigilance analysis was conducted using OpenVigil 2.1 to evaluate adverse event (AE) reports of CTS from the FAERS database from October 2003 to September 2024.”

Subjects

Patients with reported adverse events of carpal tunnel syndrome, predominantly female (69.5%) with a mean age of 57.0 years
“Female patients comprised 69.5% of CTS cases, with a mean age of 57.0±14.9 years.”

Sample size

6,837 adverse event reports involving carpal tunnel syndrome out of 12,929,504 total reports
“Of 12,929,504 AEs reported during the study period, 6,837 (0.05%) involved CTS.”

Duration

Data collection period from October 2003 to September 2024
“A retrospective pharmacovigilance analysis was conducted using OpenVigil 2.1 to evaluate adverse event (AE) reports of CTS from the FAERS database from October 2003 to September 2024.”

Reported findings

Ten drugs, including idursulfase, galsulfase, and anastrozole, were identified as having significant overreporting of carpal tunnel syndrome
“Ten drugs were found to have significant overreporting of CTS, including idursulfase (ROR=51.2, 95% CI=39.0-67.2), galsulfase (ROR=26.8, 95% CI=17.2-41.7), laronidase (ROR=20.9, 95% CI=14.4-30.3), tesamorelin (ROR=20.7, 95% CI=13.7-31.3), anastrozole (ROR=20.6, 95% CI=17.0-24.9), alendronic acid (ROR=17.1, 95% CI=14.5-20.1), gamma-hydroxybutyric acid (GHB) (ROR=16.3, 95% CI=9.6-27.6), rofecoxib (ROR=16.1, 95% CI=14.3-18.2), alendronate (ROR=12.9, 95% CI=11.0-15.2), and tafamidis (ROR=12.0, 95% CI=9.2-15.7).”
Idursulfase showed the highest reporting odds ratio for carpal tunnel syndrome association
“Idursulfase emerged as the most disproportionately overreported drug for CTS in our pharmacovigilance analysis.”
The study identified potential associations between enzyme replacement therapies, aromatase inhibitors, and bisphosphonates with carpal tunnel syndrome reports
“Several drugs were disproportionately associated with CTS in the FAERS database, including enzyme replacement therapies (ERTs), aromatase inhibitors, bisphosphonates, growth hormone (GH)-releasing factor analogs, GHB, rofecoxib, and tafamidis.”

Source: PubMed 40510111 · DOI 10.7759/cureus.83972 · all study summaries

Reported findings

Ten drugs, including idursulfase, galsulfase, and anastrozole, were identified as having significant overreporting of carpal tunnel syndrome

“Ten drugs were found to have significant overreporting of CTS, including idursulfase (ROR=51.2, 95% CI=39.0-67.2), galsulfase (ROR=26.8, 95% CI=17.2-41.7), laronidase (ROR=20.9, 95% CI=14.4-30.3), tesamorelin (ROR=20.7, 95% CI=13.7-31.3), anastrozole (ROR=20.6, 95% CI=17.0-24.9), alendronic acid (ROR=17.1, 95% CI=14.5-20.1), gamma-hydroxybutyric acid (GHB) (ROR=16.3, 95% CI=9.6-27.6), rofecoxib (ROR=16.1, 95% CI=14.3-18.2), alendronate (ROR=12.9, 95% CI=11.0-15.2), and tafamidis (ROR=12.0, 95% CI=9.2-15.7).”

Idursulfase showed the highest reporting odds ratio for carpal tunnel syndrome association

“Idursulfase emerged as the most disproportionately overreported drug for CTS in our pharmacovigilance analysis.”

The study identified potential associations between enzyme replacement therapies, aromatase inhibitors, and bisphosphonates with carpal tunnel syndrome reports

“Several drugs were disproportionately associated with CTS in the FAERS database, including enzyme replacement therapies (ERTs), aromatase inhibitors, bisphosphonates, growth hormone (GH)-releasing factor analogs, GHB, rofecoxib, and tafamidis.”